Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer

What is the ideal duration of androgen deprivation therapy (ADT) for patients with intermediate-risk, high-risk, and very high-risk prostate cancer treated with radiotherapy?In this patient-level data meta-analysis of 10 266 men with prostate cancer, there was a nonlinear relative benefit of ADT duration, and the absolute benefit varied by risk group. Prolongation of ADT had a differential association with cancer-specific mortality vs other-cause mortality.The study results suggest that individualized ADT decisions are needed for patients based on prognostic risk, comorbidities, life expectancy, and patient preferences.

Corresponding Author: Daniel E. Spratt, MD, Department of Radiation Oncology, University Hospitals Seidman Cancer, Case Western Reserve University, Cleveland, OH 44106 (daniel.spratt@uhhospitals.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.